- Home
- SLRX vs BDTX Comparison
SLRX vs BDTX Comparison
Compare SLRX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- BDTX
- Stock Information
- Founded
- SLRX N/A
- BDTX 2014
- Country
- SLRX United States
- BDTX United States
- Employees
- SLRX N/A
- BDTX N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLRX Health Care
- BDTX Health Care
- Exchange
- SLRX Nasdaq
- BDTX Nasdaq
- Market Cap
- SLRX 2.9M
- BDTX 181.4M
- IPO Year
- SLRX N/A
- BDTX 2020
- Fundamental
- Price
- SLRX $5.56
- BDTX $3.16
- Analyst Decision
- SLRX
- BDTX Strong Buy
- Analyst Count
- SLRX 0
- BDTX 6
- Target Price
- SLRX N/A
- BDTX $12.50
- AVG Volume (30 Days)
- SLRX 286.4K
- BDTX 840.0K
- Earning Date
- SLRX 11-13-2025
- BDTX 11-04-2025
- Dividend Yield
- SLRX N/A
- BDTX N/A
- EPS Growth
- SLRX N/A
- BDTX N/A
- EPS
- SLRX N/A
- BDTX 0.25
- Revenue
- SLRX N/A
- BDTX $70,000,000.00
- Revenue This Year
- SLRX N/A
- BDTX N/A
- Revenue Next Year
- SLRX N/A
- BDTX N/A
- P/E Ratio
- SLRX N/A
- BDTX $12.78
- Revenue Growth
- SLRX N/A
- BDTX N/A
- 52 Week Low
- SLRX $4.50
- BDTX $1.20
- 52 Week High
- SLRX $108.00
- BDTX $6.23
- Technical
- Relative Strength Index (RSI)
- SLRX 43.47
- BDTX 58.90
- Support Level
- SLRX $4.79
- BDTX $3.13
- Resistance Level
- SLRX $5.90
- BDTX $3.43
- Average True Range (ATR)
- SLRX 0.40
- BDTX 0.18
- MACD
- SLRX 0.27
- BDTX 0.02
- Stochastic Oscillator
- SLRX 75.36
- BDTX 63.51
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.